BNT166a

Phase 2Biologic

BioNTech

BNT166a is one of 2 biologic programs targeting Mpox. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MpoxRecruiting

MpoxPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Mpox

#DrugCompanyPhaseTrials

Tpoxx

SSIGA Technologies

Approved

1 2

BNT166a

BioNTech

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Mpox

NCT07379580

Clinical

Trials by Indication[1]

Immune Response1 trial

A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines

Active, not recruiting· BioNTech logo

BioNTech·Phase 1/2·NCT05988203·96 enrolled

Mpox1 trial

Safety, Reactogenicity, and Immunogenicity of an Mpox mRNA Vaccine Candidate, BNT166a, in Healthy Participants Aged 18 Years and Older in African Countries: A Randomized, Double-blind, Placebo-controlled Phase II Trial

Recruiting· BioNTech logo

BioNTech·Phase 2·NCT07379580·310 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BNT166a. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BNT166a compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BNT166a. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioNTech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: BioNTech

BNT166a

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Immune Response1 trial

Mpox1 trial

References

Drug Info

Quick Facts

Related News